Nothing Special   »   [go: up one dir, main page]

WO2011100700A3 - Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies - Google Patents

Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies Download PDF

Info

Publication number
WO2011100700A3
WO2011100700A3 PCT/US2011/024777 US2011024777W WO2011100700A3 WO 2011100700 A3 WO2011100700 A3 WO 2011100700A3 US 2011024777 W US2011024777 W US 2011024777W WO 2011100700 A3 WO2011100700 A3 WO 2011100700A3
Authority
WO
WIPO (PCT)
Prior art keywords
broadly neutralizing
neutralizing antibodies
pathogen
recognized
discontinuous epitopes
Prior art date
Application number
PCT/US2011/024777
Other languages
French (fr)
Other versions
WO2011100700A2 (en
Inventor
Stephen Dewhurst
Mark A. Sullivan
Original Assignee
University Of Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of Rochester filed Critical University Of Rochester
Priority to US13/577,419 priority Critical patent/US8961977B2/en
Priority to CA2788972A priority patent/CA2788972A1/en
Priority to EP11742973A priority patent/EP2533807A2/en
Publication of WO2011100700A2 publication Critical patent/WO2011100700A2/en
Publication of WO2011100700A3 publication Critical patent/WO2011100700A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

The present invention relates to an anti-idiotypic polypeptide scaffold that includes two or more peptide sequences that mimic a discontinuous epitope of a pathogen that is recognized by or induces formation of a broadly neutralizing antibody. Using a fibronectin FNfn10 scaffold bearing two or more modified discontinuous loops, scaffolds that recognize broadly neutralizing antibodies in vitro and from patient serum have been identified. These scaffolds should induce an immune response or mobilize germline specificities to initiate their affinity maturation.
PCT/US2011/024777 2010-02-12 2011-02-14 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies WO2011100700A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US13/577,419 US8961977B2 (en) 2010-02-12 2011-02-14 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
CA2788972A CA2788972A1 (en) 2010-02-12 2011-02-14 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
EP11742973A EP2533807A2 (en) 2010-02-12 2011-02-14 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30409310P 2010-02-12 2010-02-12
US61/304,093 2010-02-12
US32731710P 2010-04-23 2010-04-23
US61/327,317 2010-04-23

Publications (2)

Publication Number Publication Date
WO2011100700A2 WO2011100700A2 (en) 2011-08-18
WO2011100700A3 true WO2011100700A3 (en) 2011-10-20

Family

ID=44368501

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/024777 WO2011100700A2 (en) 2010-02-12 2011-02-14 Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies

Country Status (4)

Country Link
US (1) US8961977B2 (en)
EP (1) EP2533807A2 (en)
CA (1) CA2788972A1 (en)
WO (1) WO2011100700A2 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243436A1 (en) * 2002-06-06 2003-12-22 Shohei Koide Reconstituted polypeptides
TW200531979A (en) 2003-12-05 2005-10-01 Compound Therapeutics Inc Inhibitors of type 2 vascular endothelial growth factor receptors
US8470332B2 (en) 2006-11-22 2013-06-25 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR
AU2009213141A1 (en) 2008-02-14 2009-08-20 Bristol-Myers Squibb Company Targeted therapeutics based on engineered proteins that bind EGFR
CN102099373A (en) 2008-05-22 2011-06-15 百时美施贵宝公司 Multivalent fibronectin based scaffold domain proteins
TWI496582B (en) 2008-11-24 2015-08-21 必治妥美雅史谷比公司 Bispecific egfr/igfir binding molecules
TW201138808A (en) 2010-05-03 2011-11-16 Bristol Myers Squibb Co Serum albumin binding molecules
WO2011150133A2 (en) 2010-05-26 2011-12-01 Bristol-Myers Squibb Company Fibronectin based scaffold proteins having improved stability
WO2012142515A2 (en) 2011-04-13 2012-10-18 Bristol-Myers Squibb Company Fc fusion proteins comprising novel linkers or arrangements
WO2012158678A1 (en) 2011-05-17 2012-11-22 Bristol-Myers Squibb Company Methods for maintaining pegylation of polypeptides
US9522951B2 (en) 2011-10-31 2016-12-20 Bristol-Myers Squibb Company Fibronectin binding domains with reduced immunogenicity
CN103323588A (en) * 2012-03-19 2013-09-25 郑州中道生物技术有限公司 Method for detecting canine rabies virus antibody and detection kit
IL270110B (en) 2012-09-13 2022-08-01 Bristol Myers Squibb Co Fibronectin based scaffold domain proteins that bind to myostatin
US20150361159A1 (en) 2013-02-01 2015-12-17 Bristol-Myers Squibb Company Fibronectin based scaffold proteins
EP3406629B1 (en) 2013-02-06 2020-06-24 Bristol-Myers Squibb Company Fibronectin type iii domain proteins with enhanced solubility
WO2014126871A1 (en) 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
ES2870802T3 (en) 2013-02-12 2021-10-27 Bristol Myers Squibb Co High pH Protein Refolding Methods
WO2014165093A2 (en) 2013-03-13 2014-10-09 Bristol-Myers Squibb Company Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto
CA2926262A1 (en) 2013-10-14 2015-04-23 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
CN115322253A (en) 2014-03-20 2022-11-11 百时美施贵宝公司 Stabilized fibronectin based scaffold molecules
MX2016011580A (en) 2014-03-20 2016-11-29 Bristol Myers Squibb Co Serum albumin-binding fibronectin type iii domains.
CN107001450A (en) * 2014-11-18 2017-08-01 巴斯德研究所 It is specific to the sero-group X of Neisseria meningitidis polyclonal antibody and its purposes in diagnosis
CA2968961A1 (en) 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Methods and compositions for 18f-radiolabeling of biologics
CA2994279A1 (en) 2015-08-04 2017-02-09 Duke University Genetically encoded intrinsically disordered stealth polymers for delivery and methods of using same
MX2018001964A (en) * 2015-08-24 2018-06-19 Medimmune Llc Mrka polypeptides, antibodies, and uses thereof.
CN108290941A (en) 2015-09-23 2018-07-17 百时美施贵宝公司 The seralbumin associativity fibronectin type III domain of fast dissociation rate
US11752213B2 (en) 2015-12-21 2023-09-12 Duke University Surfaces having reduced non-specific binding and antigenicity
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
WO2017210476A1 (en) 2016-06-01 2017-12-07 Duke University Nonfouling biosensors
EP3471750A4 (en) 2016-06-21 2020-02-26 Janssen Biotech, Inc. Cysteine engineered fibronectin type iii domain binding molecules
WO2018057847A1 (en) 2016-09-23 2018-03-29 Duke University Unstructured non-repetitive polypeptides having lcst behavior
AU2017378226A1 (en) 2016-12-14 2019-06-20 Janssen Biotech, Inc. CD8A-binding fibronectin type III domains
WO2018111978A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Cd137 binding fibronectin type iii domains
WO2018111976A1 (en) 2016-12-14 2018-06-21 Janssen Biotech, Inc. Pd-l1 binding fibronectin type iii domains
WO2018132732A1 (en) 2017-01-12 2018-07-19 Duke University Genetically encoded lipid-polypeptide hybrid biomaterials that exhibit temperature triggered hierarchical self-assembly
WO2018213320A1 (en) 2017-05-15 2018-11-22 Duke University Recombinant production of hybrid lipid-biopolymer materials that self-assemble and encapsulate agents
WO2019006374A1 (en) 2017-06-30 2019-01-03 Duke University Order and disorder as a design principle for stimuli-responsive biopolymer networks
US11649275B2 (en) 2018-08-02 2023-05-16 Duke University Dual agonist fusion proteins
US11512314B2 (en) 2019-07-12 2022-11-29 Duke University Amphiphilic polynucleotides
US11628222B2 (en) 2019-10-14 2023-04-18 Aro Biotherapeutics Company CD71 binding fibronectin type III domains
WO2021076574A2 (en) 2019-10-14 2021-04-22 Aro Biotherapeutics Company Fn3 domain-sirna conjugates and uses thereof
JP2023515633A (en) 2020-02-28 2023-04-13 ブリストル－マイヤーズ スクイブ カンパニー Radiolabeled fibronectin-based scaffolds and antibodies and their theranostic uses
AU2021232573A1 (en) * 2020-03-04 2022-09-08 Duke University Protein nanoparticle design and application
US20240197854A1 (en) * 2021-01-28 2024-06-20 Duke University Compositions comprising hiv envelopes to induce hiv-1 antibodies
EP4323409A2 (en) 2021-04-14 2024-02-21 ARO Biotherapeutics Company Cd71 binding fibronectin type iii domains

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117966A1 (en) * 2001-04-04 2007-05-24 Shohei Koide Alphanubeta3 integrin-binding polypeptide monobodies and their use
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2293632C (en) * 1997-06-12 2011-11-29 Research Corporation Technologies, Inc. Artificial antibody polypeptides
US7598352B2 (en) * 2000-11-17 2009-10-06 University Of Rochester Method of identifying polypeptide monobodies which bind to target proteins and use thereof
GB0611914D0 (en) 2006-06-15 2006-07-26 Teti Giuseppe Peptides that mimic non-human cross-reactive protective epitopes of the group Bmeningococcal capsulsar polysaccharide
CA2667358A1 (en) * 2006-10-23 2008-05-29 Progenics Pharmaceuticals, Inc. Modified gp140 envelope polypeptides of hiv-1 isolates, compositions, stabilized trimeric complexes, and uses thereof
US8263350B2 (en) * 2009-06-29 2012-09-11 The University Of Chicago Molecular affinity clamp technology and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070117966A1 (en) * 2001-04-04 2007-05-24 Shohei Koide Alphanubeta3 integrin-binding polypeptide monobodies and their use
WO2008143679A2 (en) * 2006-06-01 2008-11-27 Verenium Corporation Nucleic acids and proteins and methods for making and using them

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BURIONI ET AL.: "Anti-HIV-1 response elicited in rabbits by anti-idiotype monoclonal antibodies nimicking the CD4-binding site.", PLOS ONE., vol. 3, no. (10):E, 2008, pages 1 - 7, XP008163095 *
BURTON ET AL.: "HIV vaccine design and the neutralizing antibody problem.", NAT. LMMUNOL., vol. 5, no. 3, 2004, pages 233 - 236, XP002411182 *
ZWICK ET AL.: "Identification and characterization of a peptide that specifically binds the human, broadly neutralizing anti-human immunodeficiency virus type 1 antibody b12.", J. VIROL., vol. 75, no. 14, 2001, pages 6692 - 6699, XP002309577 *

Also Published As

Publication number Publication date
EP2533807A2 (en) 2012-12-19
WO2011100700A2 (en) 2011-08-18
CA2788972A1 (en) 2011-08-18
US20130039927A1 (en) 2013-02-14
US8961977B2 (en) 2015-02-24

Similar Documents

Publication Publication Date Title
WO2011100700A3 (en) Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies
MX2014000749A (en) Neutralizing anti-influenza a virus antibodies and uses thereof.
WO2010104761A3 (en) Anti-cd40 antibodies and uses thereof
JOP20200091A1 (en) Antibody neutralizing human respiratory syncytial virus
WO2010104748A3 (en) Antigen presenting cell targeted anti-viral vaccines
WO2013064700A3 (en) Chimeric human-camel antigens and their use
MX2015008847A (en) Influenza virus immunogenic compositions and uses thereof.
MX337397B (en) Antigen presenting cell targeted anti-viral vaccines.
NZ607969A (en) Cd33 binding agents
EP4070818A3 (en) Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy
TR201910721T4 (en) Antibody molecules with specificity for human OX40.
PE20130206A1 (en) MULTIVALENT ANTIBODIES ANTAGONISTS OF LRP6 (LOW DENSITY LIPOPROTEIN-RELATED PROTEIN 6) AND COMPOSITIONS
NZ709390A (en) Folate receptor 1 antibodies and immunoconjugates and uses thereof
WO2010010466A3 (en) Neutralizing anti-influenza a virus antibodies and uses thereof
GB201212940D0 (en) Antibodies to highly conserved targets
HRP20190752T1 (en) Novel anti-human tslp receptor antibody
MX2013007918A (en) Monomeric and multimeric immunogenic peptides.
WO2012064760A3 (en) Materials and methods for directing an immune response to an epitope
AU2015287227A8 (en) Immune-stimulating monoclonal antibodies against human interleukin-2
UA110024C2 (en) VACCINE VECTOR AND METHOD OF IMMUNE IMPROVEMENT
WO2011153380A3 (en) Humanized monoclonal antibodies and methods of use
MY166152A (en) Anti-human xcr1 antibodies
WO2014016702A3 (en) Humanized forms of monoclonal antibodies to human gnrh receptor
FR2998579B1 (en) METHOD FOR OBTAINING ANTIGEN-SPECIFIC HUMAN ANTIBODIES BY IN VITRO IMMUNIZATION
MY166974A (en) Anti-human epo receptor antibodies and method of use

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11742973

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2011742973

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2788972

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13577419

Country of ref document: US